Print

Evonik achieves major biotech breakthrough with a new animal-free and fermentation-based collagen platform

Evonik has just announced the development of an advanced collagen platform that is made via fermentation-based processes and devoid of animal- or human-derived materials. The recombinant technology will, for the first time, provide pharmaceutical, medical, cell culture and tissue engineering markets with a highly soluble, ultra-pure form of collagen that is safe, sustainable and commercially scalable. 

“This is arguably our biggest innovation breakthrough in recent years: a fermentation-based collagen platform that can effectively substitute the use of animal-derived collagen in pharmaceutical, medical, and cell culture markets.” said Dr. Thomas Riermeier, SVP and General Manager for the Health Care business line of Evonik.  “We look forward to working with customers to develop the next-generation collagen products with an improved safety profile.” 

“Biotechnology is an important lever for growth and innovation within Evonik Nutrition & Care that leverages our core competencies across fermentation, biomaterials and product industrialization,” said Johann-Caspar Gammelin, Chairman of the Board of Management of Evonik Nutrition & Care.

2020 03 20 103655

The new collagen platform strongly complements other recent fermentation-driven biotech breakthroughs that have been pioneered by Evonik, including biosurfactants for household and cosmetic applications (rhamnolipids) and omega-3 fatty acids from natural marine algae for animal nutrition (Veramaris). 

Evonik’s proprietary collagen platform features a triple helix structure and other biological properties that mimic many of the attributes of natural collagen so it can reliably interact with cells and tissues and be readily absorbed or remodelled by the body.

Animal-sourced collagen, currently the main source of collagen for use in life sciences, can be associated with batch-to-batch variability, potential transmission of diseases or pathogens, adverse immunogenic or allergic reactions, and non-sustainable sourcing methods. Evonik’s collagen is produced under controlled conditions via a fermentation-based process. In addition to being sustainable and suitable for vegan use, this process delivers an ultra-high level of purity that is easily reproducible at any commercial scale. 

Evonik will utilize its established fermentation process technologies and global manufacturing network to commercialize the collagen platform for worldwide use. The Company’s application, formulation and manufacturing competencies will also be used to help customers develop and commercialize their own biofabricated products. 

The new collagen platform will also support Evonik’s Tissue Engineering Project House, which was launched in Singapore in 2018 by the Company’s strategic innovation unit Creavis, to develop advanced biomaterial solutions in regenerative medicine.

About the collagen market

Collagen is the main structural protein family in the body, contributing between a quarter and one third of total protein mass in humans and other mammals. It is important in the formation and functionality of body parts such as skin, tissue, cartilage, organs, bone, bone marrow, cell membranes, ligaments and hair. It is commonly used as a biomaterial in health care due to its biocompatibility, degradability and structural properties that enable cell and tissue interaction. Product application areas include orthopedics, cardiovascular, wound care, ocular care, general surgery, dental care, drug delivery and regenerative medicine. Virtually all medical and pharmaceutical-grade collagen used today is derived from animal-based sources.

Print

CSafe Global Names Patrick Schafer Chief Executive Officer

CSafe Global’s Board of Directors has named Patrick Schafer as the company’s new CEO. Schafer, previously CSafe’s Chief Financial Officer, steps into the role after serving as the company’s interim CEO since September.  

CSafe Global, the leader in temperature-controlled container solutions for the transport of life-enhancing pharmaceuticals and the fast-growing cell and gene market, announced today that Patrick Schafer has been named as the company’s new Chief Executive Officer.  

Bill Mitchell, Chairman of PCI Pharma Services and a CSafe Global board member made the announcement to CSafe Global employees at the company’s headquarters and via video conference to its more than 200 employees worldwide. Mitchell had this to say: “Mr. Schafer’s unmatched knowledge and understanding of the industry and the CSafe organization, along with the exceptional rapport he’s built with the team during his 8-year tenure will help him lead CSafe to new levels of success. The entire board believes in this business and we are confident that Mr. Schafer will continue to drive growth and deliver excellent products and service to our customers.”  

Bill Mitchell (left), Chairman of PCI Pharma Services and a CSafe Global board member, congratulating Patrick Schafer, CSafe Global CEOBill Mitchell (left), Chairman of PCI Pharma Services and a CSafe Global board member, congratulating Patrick Schafer, CSafe Global CEO

Schafer began his career at CSafe in 2012 as the Chief Financial Officer and has been serving as the interim CEO since September 2019. A dual U.S. and European citizen, Mr. Schafer has broad international experience having spent part of his career living and working in Europe.

“CSafe is an extraordinary company – one that I am honored to have the opportunity to lead,” said Schafer. “We have the best products in the industry, the best service and support, and the best team of innovative thinkers in our space. I have no doubt CSafe will continue to be the premier provider of cold chain shipping solutions and I am thrilled to help our entire team around the world work toward our goals.”

With the executive team now in place, the industry can expect to see much more from CSafe in the coming months and years. Schafer added, “We’ve made significant additions to our team and have rapidly expanded our active container fleet. We have an unrivaled global footprint and are eager to share our world-class cell and gene solutions and our new artificial intelligence platform. We are poised to not only fulfill current customer demand, but also provide exceptional solutions well into the future.” 

About CSafe Global

CSafe Global provides end-to-end thermal shipping solutions to the pharmaceutical and life science industries worldwide. Using its proprietary, fully-integrated artificial intelligence capability, CSafe ensures containers are available when and where customers need them. Combined with the company’s industry-leading retest and reuse program, all CSafe customers are assured ongoing superior product performance for every shipment that also meets customers' sustainability objectives. With a presence in 150 countries, CSafe is committed to providing its solutions on-demand 24/7 with a 100% guarantee, thus making CSafe the partner of choice for the most challenging customers in the cold chain.

CSafeGlobal.com

Print

CSafe expands service center in South Korea for active temperature-controlled containers

CSafe Global announces the opening of a newly-expanded service center in Incheon. The company-owned facility will allow CSafe to enhance support and service for customers transporting temperature-sensitive products to and from South Korea, while additionally serving as an important gateway hub for the greater APAC region.

CSafe Global, the innovation leader in active temperature-controlled container solutions for the transport of life-enhancing pharmaceuticals, widens its operational footprint with the opening of an enlarged and expanded service center facility at Incheon International Airport (ICN). The new service center was strategically implemented to accommodate the growing demand for CSafe’s specialized air cargo containers in South Korea, and throughout the broader Asia Pacific region.

CSafe’s ICN station is one of the latest of numerous locations around the world established to broaden CSafe’s global service reach and increase the impact on customers who have entrusted CSafe containers to thermally protect vital life-enhancing pharmaceuticals as they are shipped to patients in need.

2020 01 22 081624

“We’re excited about our best-in-class service center in Incheon. This new facility will ensure that our active containers are operating at top system performance, keeping temperatures precisely where they need to be for transports of crucial medications. Our service team has been trained and is well prepared to address the significant volume demand for CSafe RKN and CSafe RAP containers from the Incheon station,” said Tom Weir, VP of Global Operations at CSafe Global.

“With the expanded warehouse space and increased repair service throughput, not only can we easily accommodate the increasing product demand from South Korea, but we also strengthen our ability to flex as needed for repositioning large numbers of our temperature-controlled containers to other CSafe hubs within Asia Pacific to meet unexpected or immediate surge demand from our customers and partners across the region.”                                                               

To verify that CSafe RKN and CSafe RAP systems are of highest quality and in peak condition, all containers entering CSafe service centers are put through an industry-unique Preventative Maintenance Rebuild (PMR) program to certify optimal operational performance. This protocol goes a long way in providing peace of mind to CSafe customers, while delivering on the CSafe promise to protect what matters most to pharmaceutical companies, so patients can receive what matters most to them.

To upgrade to a higher level of performance and thermal protection when shipping life-enhancing pharmaceuticals, please contact Scott Garchar, Senior Director of Life Sciences – Asia (sgarchar@csafeglobal.com).

About CSafe Global

CSafe Global provides end-to-end thermal shipping solutions to the pharmaceutical and life science industries worldwide. Using its proprietary, fully-integrated Artificial Intelligence capability, CSafe ensures containers are available when and where customers need them. Combined with the company’s industry-leading retest and reuse program, all CSafe customers are assured ongoing superior product performance for every shipment that also meets customers' sustainability objectives. With a presence in 150 countries, CSafe is committed to providing its solutions on-demand 24/7 with a 100% guarantee, thus making CSafe the partner of choice for the most challenging customers in the cold chain.

CSafeGlobal.com

Print

Brenntag opens new warehouse facility in Dongguan, South China

Brenntag, the global market leader in chemical and ingredients distribution, today announces the inauguration of a new warehouse facility in Dongguan, South China. The newly built facility is located in the province of Guangdong which is one of the largest economic provinces in China. Operations have already started.

Henri Nejade, Member of the Management Board of Brenntag Group and CEO Brenntag Asia Pacific: “We are excited about the start of our operations at Dongguan as its capabilities and ideal location will certainly enhance our position in the South China market and further enable Brenntag to provide more value-added services to our customers and suppliers.”

2020 01 21 225354

On an area of around 39,000 m2, the new Brenntag site features 24 storage tanks, 3,000 m2 storage area for Class A chemicals and a 2,500 m2 workshop and blending area for both solvents and inorganic chemicals. The Dongguan facility complies with highest safety and environmental restrictions and is located in a dedicated chemical park. Safety is always a top priority at Brenntag. Worldwide, the company operates in accordance with the “Safety First” principle as its most important value.

About Brenntag:

Brenntag is the global market leader in chemical and ingredients distribution. We connect our suppliers and customers in value-adding partnerships. Our more than 16,600 employees provide tailor-made application, marketing and supply chain solutions. Technical and formulation support, market, industry and regulatory expertise as well as advanced digital tools are just some examples of our services that are aiming to create an excellent customer experience.
Our full-line portfolio comprises specialty and industrial chemicals and ingredients of a world-class supplier base. Building on its long-standing experience, unmatched global reach and local excellence, Brenntag works closely alongside its partners to make their business more successful. We are committed to contribute towards greater sustainability in our own business and the industries we serve, and to achieve sustainable profitable growth. Headquartered in Essen (Germany) and with regional headquarters in Philadelphia, Houston and Singapore, Brenntag operates a unique global network with more than 580 locations in 76 countries and generated sales of EUR 12.6 billion (USD 14.8 billion) in 2018. Brenntag shares are traded at the Frankfurt Stock Exchange (BNR).

Print

BASF expands production capacity for Irganox® 1520L in Pontecchio Marconi, Italy

BASF plans to increase the production capacity for its antioxidant Irganox® 1520L by 20% at the site in Pontecchio Marconi, Italy. Irganox® 1520L is a key product in BASF’s antioxidant portfolio. The company is a leading global supplier for plastic additives. With this expansion, BASF responds to an increasing market demand and aims to better serve its global customers.

  • Investment meets increasing global demand
  • Annual capacity expansion of 20%
  • Startup planned for the first quarter of 2021

“The production expansion of Irganox® 1520L underlines our clear commitment to continuously support the growth of our customers. By debottlenecking operations at our Pontecchio plant in Italy, we are able to respond quickly to an increasing market demand,” says Achim Sties, Senior Vice President, Performance Chemicals Europe, BASF.

Irganox® 1520L is a highly effective thermo-oxidative stabilizer in a wide range of solution polymerized, emulsion polymerized and thermoplastic elastomers, plastics, adhesives, sealants, oils and lubricants. It is unique in its ability to provide both processing and long-term heat-aging stability used alone, at low levels and without co-stabilizers. Where necessary, Irganox® 1520L can be used with other additives such as secondary antioxidants, benzofuranone, light stabilizers and other functional stabilizers.

BASF will add 20% to its existing capacity for Irganox® 1520L at its Pontecchio Marconi production plant in Italy by debottlenecking operations.BASF will add 20% to its existing capacity for Irganox® 1520L at its Pontecchio Marconi production plant in Italy by debottlenecking operations.

About BASF Plastic Additives

BASF is a leading supplier, manufacturer and innovation partner of plastic additives. Its comprehensive and innovative product portfolio includes stabilizers which provide ease in processing, heat and light resistance to a variety of polymers and applications including molded articles, films, fibers, sheets and extruded profiles. More information about plastic additives: www.plasticadditives.basf.com.

BASF Plastic Additives is part of BASF’s Performance Chemicals division. The division’s portfolio also includes Fuel and Lubricant Solutions, Kaolin Minerals, as well as Oilfield and Mining Solutions. Customers from a variety of industries including Chemicals, Plastics, Consumer Goods, Energy & Resources and Automotive & Transportation benefit from our innovative solutions. To learn more, visit http://www.performancechemicals.basf.com.

About BASF

At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. The approximately 122,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of around €63 billion in 2018. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the U.S. Further information at www.basf.com